Weeks after its denial, New York Stock Exchange (NYSE)-listed Taro Pharmaceutical Industries finally gave its approval to be taken private by Sun Pharmaceutical Industries, for an all cash deal valued at $571.3 million against the earlier denied offer of $367 million. Drug maker, Sun Pharmaceutical and its affiliates collectively owned about 66% of the outstanding Taro ordinary shares and 100% of Tarot’s founder shares, representing about 77.5% of the outstanding voting power in Taro. Meanwhile, the remaining 44.5 million outstanding shares, translating into 22.5% of the complete stake, will be acquired by the company at cash payment of $39.50 per share against the earlier rejected offer $24.50 per share from the Tarot’s shareholders.
On completion of the merger by both the companies, Taro would turn into privately held company, wholly owned by Sun Pharmaceuticals and its affiliates. Further, the merger was approved by Taro’s board of directors based upon the recommendations and approvals of the Special Committee of Taro’s board of directors and the Audit Committee of the company’s board.
Recently, Sun Pharmaceutical Industries has received an approval to spin-off the domestic formulation business of the company on a going concern basis comprising certain assets pertaining to the said business to its wholly owned subsidiary (WOS), Sun Resins & Polymers with effect from March 31, 2012.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: